Genzyme Tolevamer Represents New Market Opportunity
Launch of the non-antibiotic treatment for Clostridium difficile colitis would require the biotech to build or acquire a hospital sales force.
Launch of the non-antibiotic treatment for Clostridium difficile colitis would require the biotech to build or acquire a hospital sales force.